ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

New Drug Class Could Fill Unmet Need in Treatment of Multiple Myeloma

A new class of drugs designed to attack malignant plasma cells could offer patients with multiple myeloma new treatment options, according to early clinical...

Brentuximab Vedotin Delivers Clinical Results in Both Pre- and Post-Transplant Hodgkin Lymphoma

Brentuximab vedotin, an antibody-drug conjugate that targets CD30-positive cells, was the focus of much attention at the 56th ASH Annual Meeting. Two studies highlighted...

Update on Idelalisib + Rituximab in Relapsed and Elderly CLL Patients

The combination of idelalisib with rituximab prolonged progression-free survival (PFS) for patients with relapsed chronic lymphocytic leukemia (CLL), according to an oral presentation at...

Rising Cost of Cancer Drugs: Is There an End in Sight?

In 2013, U.S. health-care spending continued its relentless climb, reaching $2.9 trillion, far outspending any other developed nation.¹ About $271.1 billion of that – or almost one...

For ASCT in Myeloma, Does One Size Fit All?

SAN FRANCISCO — Drug development for multiple myeloma in the last decade has reached an unprecedented pace, expanding to include regimens with novel agents like...

Addition of Third Drug to Multiple Myeloma Regimen Slows Progression of Disease

A new research study has found that adding carfilzomib to a treatment regimen of lenalidomide and dexamethasone significantly improved progression-free survival (PFS) in patients...

New Compound Boosts Healthy Red Blood Cell Production, Lowers Anemia Burden in β-Thalassemia

ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, has shown promising results in the treatment of β-thalassemia, reducing the need for...

HSCT Could Become Standard of Care for HIV-Positive Patients with Lymphoma

Results from a multi-institutional trial presented at ASH 2014 debunk the common myth that HIV-positive patients with lymphoma might not be suitable for autologous hematopoietic stem cell...

Ibrutinib + Rituximab Benefits Patients With Pre-Treated Lymphoma and Leukemia

The combination of ibrutinib and rituximab is a promising treatment option for patients with relapsed or refractory blood cancers, according to results of two...

PD-1 Checkpoint Inhibitors Harness the Immune System to Treat Lymphomas

A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed and refractory lymphomas, according to...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.